Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06577532
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-22
Brief Title:
Study of KRAS Neoantigen mRNA Vaccine ABO2102 in Patients With KRAS -Mutated Advanced Pancreatic Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Clinical Study to Investigate Safety Tolerability Immunogenicity and Preliminary Anti-Tumor Activity of KRAS Neoantigen mRNA Vaccine ABO2102 in Participants With KRAS-mutated Advanced Pancreatic Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety immunogenicity pharmacodynamics as well as preliminary anti-tumor activity of KRAS neoantigen mRNA vaccine ABO2102 alone and in combination with toripalimab anti-PD-1 monoclonal antibody among participants with KRAS-mutated advanced pancreatic cancer The trial includes dose escalation Part I and dose expansionPart II parts
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None